Impact of MDR1 and CYP3A5 on the oral clearance of tacrolimus and tacrolimus-related renal dysfunction in adult living-donor liver transplant patients.
about
Determination of the most influential sources of variability in tacrolimus trough blood concentrations in adult liver transplant recipients: a bottom-up approachMeasurement and compartmental modeling of the effect of CYP3A5 gene variation on systemic and intrarenal tacrolimus disposition.PharmGKB summary: cyclosporine and tacrolimus pathwaysAssociation of MDR1 gene SNPs and haplotypes with the tacrolimus dose requirements in Han Chinese liver transplant recipients.Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing.Genetic and clinical determinants of early, acute calcineurin inhibitor-related nephrotoxicity: results from a kidney transplant consortium.Unmet medical needs in lupus nephritis: solutions through evidence-based, personalized medicineThe 6R's of drug induced nephrotoxicityCombinational effect of intestinal and hepatic CYP3A5 genotypes on tacrolimus pharmacokinetics in recipients of living donor liver transplantation.Population pharmacokinetics and pharmacogenetics of once daily tacrolimus formulation in stable liver transplant recipients.Influence of Absorption, Distribution, Metabolism, and Excretion Genomic Variants on Tacrolimus/Sirolimus Blood Levels and Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation.Immunological aspects in late phase of living donor liver transplant patients: usefulness of monitoring peripheral blood CD4+ adenosine triphosphate activity.Pharmacogenetic considerations for optimizing tacrolimus dosing in liver and kidney transplant patientsImmune response following liver transplantation compared to kidney transplantation: usefulness of monitoring peripheral blood CD4+ adenosine triphosphate activity and cytochrome P450 3A5 genotype assay.CYP3A polymorphisms and immunosuppressive drugs in solid-organ transplantation.Population pharmacokinetic and pharmacogenetic analysis of tacrolimus in paediatric liver transplant patients.The missing linkage: what pharmacogenetic associations are left to find in CYP3A?Integrating genomics into biobehavioral research: a transplantation exemplar.High tacrolimus blood concentrations early after lung transplantation and the risk of kidney injuryImpact of ATP-binding cassette, subfamily B, member 1 pharmacogenetics on tacrolimus-associated nephrotoxicity and dosage requirements in paediatric patients with liver transplant.Deciphering calcineurin inhibitor nephrotoxicity: a pharmacological approach.Ontogeny of oral drug absorption processes in children.Developmental changes in the expression and function of cytochrome P450 3A isoforms: evidence from in vitro and in vivo investigations.Early use of renal-sparing agents in liver transplantation: a closer look.Pharmacogenetics in solid organ transplantation: genes involved in mechanism of action and pharmacokinetics of immunosuppressive drugs.The role of pharmacogenetics in the disposition of and response to tacrolimus in solid organ transplantation.In vitro experimental system for evaluating inhibitory effect of investigational drugs on P-glycoprotein-mediated transcellular transport of tacrolimus (FK506).Drug metabolism and liver disease: a drug-gene-environment interaction.Update on the clinical pharmacogenomics of organ transplantation.Engraftment syndrome, but not acute GVHD, younger age, CYP3A5 or MDR1 polymorphisms, increases tacrolimus clearance in pediatric hematopoietic SCT.Effects of CYP3A5 genotypes, ABCB1 C3435T and G2677T/A polymorphism on pharmacokinetics of Tacrolimus in Chinese adult liver transplant patients.CYP3A5 genotypes affect tacrolimus pharmacokinetics and infectious complications in Chinese pediatric liver transplant patients.Prospective evaluation of the bayesian method for individualizing tacrolimus dose early after living-donor liver transplantation.Tacrolimus Concentration in Saliva of Kidney Transplant Recipients: Factors Influencing the Relationship with Whole Blood Concentrations.FOXP3 rs3761548 polymorphism is associated with tacrolimus-induced acute nephrotoxicity in renal transplant patients.Artificial neural network model for predicting the bioavailability of tacrolimus in patients with renal transplantation.Pharmacogenotyping of CYP3A5 in predicting dose-adjusted trough levels of tacrolimus among Malaysian kidney-transplant patients.CYP3A5 polymorphisms in renal transplant recipients: influence on tacrolimus treatment.
P2860
Q33574176-00F7B19C-F060-4060-8F5C-8E8475607A8FQ33683838-2D364E0A-7741-4C17-839E-904775515354Q33989902-0A19F151-649E-4C39-ABC1-C1456A68D237Q34081393-7BEE7C89-64ED-4389-A1C3-8DEB8527BDB6Q35782898-38604F0A-8C5F-4A20-9B77-8F247C96610AQ35823308-2C49D836-62C5-48F5-90DD-A36B3D7A5991Q36088877-42011788-8A7B-402C-9AB0-C9F3BE6F426EQ36333140-ACD1431A-8FD1-43C4-9901-E8DD88007B42Q36339420-5FFEB8A4-CAD8-419D-B8EC-C86DCF4DF54CQ36465101-DC6C0453-C9B4-48BA-AE8A-381F38323834Q36474050-112FBAB5-F099-41BA-A413-2A22851C2B2DQ37243098-99321944-4F51-477A-B576-F02288F12726Q37439873-DB7A4BA3-C649-4038-910F-A00347894F1DQ37456878-4A2F3CE4-5318-409D-AC72-95B5244500B5Q37478703-AF8C1C32-4B07-46A7-A743-14ACE1212FCAQ37492036-9D27EA5B-F6FA-47AB-A8F1-A61F50C0CC58Q37646778-229D285E-9D18-4935-89CE-2D17D26385ECQ37665269-2C21AA4F-010D-4725-AA99-20C929130453Q37742226-89A4BA4D-B928-440B-942F-0C99838B8EFFQ37772515-D5C38F45-0E69-48D2-A069-3FAADFF61F5DQ37806767-F8F5BAD4-7867-4E46-8A1A-1FF59D6FA155Q38017723-F8E0E8F8-AC59-435A-9512-768D8B0766A3Q38086777-A3872220-072E-4534-BAC1-2035C0CC13B5Q38108593-3C51204C-0B44-4E4C-8BFF-86E6C7AE4B3EQ38120290-B8F03F43-21CE-42CE-BE0E-337D4E66E058Q38163945-51C132F0-6D4B-4A22-B888-B6AD874F00FBQ38995566-31D172F3-0905-4A1E-88EA-D277A4A95151Q39037269-D5D14503-B51F-4B48-814D-E69B1154211BQ39903042-3609E962-4CB5-40B9-A956-C94091CB0AEFQ40361644-CCA7C75F-EB2A-4FB2-8712-93AFD4EFF0B4Q41079423-F0AF1D2F-B2A8-4BA5-A813-D99F3503B12BQ42232484-5BC0BB80-A292-4976-A607-EE3475F1957CQ45987182-B4750E46-E9AE-42E8-81BD-F4CD88B2CAF4Q48250195-833696D1-08A8-43F2-B964-E7AA289FA74FQ51387694-70AAA777-CD7A-437B-B1AA-CF2E65DA91D3Q53278594-62EF369B-5F44-4ECE-AADF-AD044BFF4BDAQ54378695-AF2C0BA2-EC8F-4CD2-8ACE-D85A5BA2FF59Q55280859-0D2E8B47-26E7-4B7F-B864-30D9C7FD019A
P2860
Impact of MDR1 and CYP3A5 on the oral clearance of tacrolimus and tacrolimus-related renal dysfunction in adult living-donor liver transplant patients.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Impact of MDR1 and CYP3A5 on t ...... nor liver transplant patients.
@en
Impact of MDR1 and CYP3A5 on t ...... nor liver transplant patients.
@nl
type
label
Impact of MDR1 and CYP3A5 on t ...... nor liver transplant patients.
@en
Impact of MDR1 and CYP3A5 on t ...... nor liver transplant patients.
@nl
prefLabel
Impact of MDR1 and CYP3A5 on t ...... nor liver transplant patients.
@en
Impact of MDR1 and CYP3A5 on t ...... nor liver transplant patients.
@nl
P2093
P1476
Impact of MDR1 and CYP3A5 on t ...... nor liver transplant patients.
@en
P2093
Atsushi Yoshimura
Fumitaka Oike
Ikuko Yano
Keiko Hosohata
Ken-ichi Inui
Masahide Fukudo
Miwa Uesugi
Satohiro Masuda
Shinji Uemoto
Toshiya Katsura
P304
P356
10.1097/FPC.0B013E3282F9AC01
P577
2008-05-01T00:00:00Z